CERo Therapeutics updates on its Phase 1 trial of CER-1236, with the second patient now undergoing evaluations.
Quiver AI Summary
CERo Therapeutics Holdings, Inc. announced the dosing of the second patient in its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML) at the Sarah Cannon Research Institute in Denver. Following the infusion, the patient is undergoing evaluations for safety, tolerability, and efficacy. Preliminary results from the first patient show significant expansion of the infused CAR-T cells, indicating potential effectiveness of the CER-1236 therapy. The trial aims to assess the safety and preliminary efficacy of CER-1236, focusing on specific endpoints like adverse events and overall response rates, as researchers continue to monitor pharmacokinetics. CERo's CEO expressed optimism about the progress, highlighting the significance of these results in advancing cancer immunotherapy treatments.
Potential Positives
- Second patient has been dosed in the Phase 1 CER-1236 clinical trial, demonstrating progress in the study's timeline and patient recruitment.
- First patient showed no dose-limiting toxicities, which may indicate a favorable safety profile for the therapy.
- Pharmacokinetic results from the first patient show significant expansion of infused cells, suggesting potential efficacy of CER-1236 in treating acute myeloid leukemia.
- Company is advancing a novel approach to cancer immunotherapy, potentially expanding therapeutic applications beyond current CAR-T cell therapies.
Potential Negatives
- Press release emphasizes the preliminary nature of results, which may indicate the ongoing uncertainty surrounding the success of CER-1236 in clinical trials.
- The mention of monitoring for adverse events and dose-limiting toxicities highlights potential safety concerns with the treatment that could arise as the patient cohort expands.
- The heavy reliance on forward-looking statements and cautionary notes suggests that the company's future performance is unpredictable and dependent on various risks, which may concern investors.
FAQ
What is the focus of the CER-1236 clinical trial?
The CER-1236 clinical trial focuses on treating patients with acute myeloid leukemia (AML).
Where was the second patient in the trial dosed?
The second patient was dosed at the Sarah Cannon Research Institute in Denver, Colorado.
What are the primary outcome measures of the trial?
The primary outcome measures include adverse events, dose-limiting toxicities, and overall response rates.
What does CER-1236 aim to achieve in cancer treatment?
CER-1236 aims to optimize cancer therapy by integrating innate and adaptive immunity into T cell therapeutics.
What was the result for the first patient in the trial?
The first patient experienced no dose-limiting toxicities and showed rapid expansion of infused cells post-infusion.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CERO Hedge Fund Activity
We have seen 0 institutional investors add shares of $CERO stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARCH VENTURE MANAGEMENT, LLC removed 9,393,561 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6,857,299
- CUBIST SYSTEMATIC STRATEGIES, LLC removed 333,442 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $243,412
- CANTOR FITZGERALD, L. P. removed 155,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $113,150
- MILLENNIUM MANAGEMENT LLC removed 63,054 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $46,029
- AVANTAX PLANNING PARTNERS, INC. removed 25,852 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,871
- VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC removed 2,347 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,713
- GOLDMAN SACHS GROUP INC removed 1,625 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,186
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CERO Analyst Ratings
Wall Street analysts have issued reports on $CERO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 06/24/2025
- Maxim Group issued a "Buy" rating on 05/19/2025
To track analyst ratings and price targets for $CERO, check out Quiver Quantitative's $CERO forecast page.
$CERO Price Targets
Multiple analysts have issued price targets for $CERO recently. We have seen 2 analysts offer price targets for $CERO in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $30.0 on 06/24/2025
- Jason McCarthy from Maxim Group set a target price of $60.0 on 05/19/2025
Full Release
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results
SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The patient was dosed at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado, with Yazan Migdady, M.D., an associate member physician at CBCI acting as principal investigator for the study. With more than seven days passed following the second patient’s infusion, monitoring continues for key safety, tolerability, and efficacy endpoints.
Dr. Migdady noted, “The dosing of the second patient in this Phase 1 first-in-human trial is an important indicator, representing a key clinical development milestone for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L. We believe that CER-1236 may be an important advancement in cancer immunotherapy and this second patient reflects steady progress in our clinical evaluation. We are now conducting protocol-specified evaluations of safety, pharmacodynamic, pharmacokinetic, and efficacy endpoints, and expect to communicate progress over the course of the study.”
Previously CERo reported that the first patient treated in CertainT-1 had no dose-limiting toxicities during the 28-day DLT observation period. Further analysis of CER-1236 pharmacokinetics in this patient reveals that the therapy of infused cells expanded (e.g., the cell number multiplied) as expected upon infusion, reaching a peak at 14 days post infusion with a 20.8-fold expansion of infused cells. These are early insights into how CER-1236 functions in AML patients, and CERo will be monitoring pharmacokinetics in subsequent patients.
The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study has begun with dose escalation to determine the highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK).
CERo CEO Chris Ehrlich said, “We are encouraged that in our very first patient treated we saw rapid and significant expansion in CER-1236 cells after infusion, a positive sign that we’re on the right track in our Phase I study, based on the extensive experience and history of the clinical development of CAR T cells. We continue to believe that CER-1236 is a novel approach to treating cancer, and we are grateful for the participation of our first and second patients, and to the many people who have worked tirelessly to reach this milestone, including our CERO team, our consultants and study sites. We look forward to discussing additional outcomes, which we anticipate will validate the scientific work performed to date with CER-1236.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
[email protected]
Investors:
CORE IR